S. I. Blot, F. Pea, and J. Lipman, The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents, Adv Drug Deliv Rev, vol.77, pp.3-11, 2014.

F. Pea, P. Viale, F. Pavan, and M. Furlanut, Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy, Clin Pharmacokinet, vol.46, issue.12, pp.997-1038, 2007.

F. S. Taccone, P. Laterre, T. Dugernier, H. Spapen, I. Delattre et al., Insufficient ?-lactam concentrations in the early phase of severe sepsis and septic shock, Crit Care Lond Engl, vol.14, issue.4, p.126, 2010.

M. Ulldemolins, J. A. Roberts, J. Rello, D. L. Paterson, and J. Lipman, The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients, Clin Pharmacokinet, vol.50, issue.2, pp.99-110, 2011.

J. Gonçalves-pereira and P. Póvoa, Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of ?-lactams, Crit Care Lond Engl, vol.15, issue.5, p.206, 2011.

A. Kumar, D. Roberts, K. E. Wood, B. Light, J. E. Parrillo et al., Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, Crit Care Med, vol.34, issue.6, pp.1589-96, 2006.

M. Iregui, S. Ward, G. Sherman, V. J. Fraser, and M. H. Kollef, Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia, Chest, 2002.

M. Leone, A. Bourgoin, S. Cambon, M. Dubuc, J. Albanèse et al., Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome, Crit Care Med, vol.31, issue.2, pp.462-469, 2003.

R. Guilhaumou, S. Benaboud, Y. Bennis, C. Dahyot-fizelier, E. Dailly et al., Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR), Crit Care Lond Engl, vol.23, issue.1, p.104, 2019.

J. A. Roberts, A. Davis, J. S. Dulhunty, J. M. Cotta, M. O. Myburgh et al., Continuous versus Intermittent ?-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials, Am J Respir Crit Care Med, vol.15, issue.6, pp.681-91, 2016.

A. Lal, P. Jaoude, and A. A. El-solh, Prolonged versus Intermittent Infusion of ?-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother, vol.48, pp.81-90, 2016.

Y. R. Lee, P. D. Miller, S. K. Alzghari, D. D. Blanco, J. D. Hager et al., Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis, Eur J Drug Metab Pharmacokinet, vol.43, issue.2, pp.155-70, 2018.

W. A. Krueger, J. Bulitta, M. Kinzig-schippers, C. Landersdorfer, U. Holzgrabe et al., Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers, Antimicrob Agents Chemother, vol.49, issue.5, pp.1881-1890, 2005.

J. W. Mouton and J. G. Hollander, Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model, Antimicrob Agents Chemother, vol.38, issue.5, pp.931-937, 1994.

P. Longuet, A. L. Lecapitaine, B. Cassard, R. Batista, R. Gauzit et al., Preparing and administering injectable antibiotics: How to avoid playing God, Med Mal Infect, 2016.

C. Li, X. Du, J. L. Kuti, and D. P. Nicolau, Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections, Antimicrob Agents Chemother, vol.51, issue.5, pp.1725-1755, 2007.

J. W. Mouton, N. Punt, and A. A. Vinks, Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo, Antimicrob Agents Chemother, vol.51, issue.9, pp.3449-51, 2007.

M. Beumier, G. S. Casu, M. Hites, F. Wolff, F. Cotton et al., Elevated ?-lactam concentrations associated with neurological deterioration in ICU septic patients, Minerva Anestesiol, vol.81, issue.5, pp.497-506, 2015.

T. M. Chapuis, E. Giannoni, P. A. Majcherczyk, R. Chioléro, M. Schaller et al., Prospective monitoring of cefepime in intensive care unit adult patients, Crit Care Lond Engl, vol.14, issue.2, p.51, 2010.

G. Naeije, S. Lorent, J. Vincent, and B. Legros, Continuous epileptiform discharges in patients treated with cefepime or meropenem, Arch Neurol, vol.68, issue.10, pp.1303-1310, 2011.

M. Verdier, O. Tribut, P. Tattevin, L. Tulzo, Y. Michelet et al., Simultaneous Determination of 12 ?-Lactam Antibiotics in Human Plasma by High-Performance Liquid Chromatography with UV Detection: Application to Therapeutic Drug Monitoring, Antimicrob Agents Chemother, vol.55, issue.10, pp.4873-4882, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00875271

T. Legrand, D. Vodovar, N. Tournier, N. Khoudour, and A. Hulin, Simultaneous Determination of Eight ?-Lactam Antibiotics, Oxacillin, and Piperacillin, in Human Plasma by Using Ultra-High-Performance Liquid Chromatography with Ultraviolet Detection, vol.60, pp.4734-4776, 2016.

M. H. Abdul-aziz, J. Lipman, M. Akova, M. Bassetti, J. J. De-waele et al., Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort, J Antimicrob Chemother, vol.71, issue.1, pp.196-207, 2016.

J. A. Roberts, J. Lipman, S. Blot, and J. Rello, Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care, vol.14, pp.390-396, 2008.

F. Thalhammer, F. Traunmüller, E. Menyawi, I. Frass, M. Hollenstein et al., Continuous infusion versus intermittent administration of meropenem in critically ill patients, J Antimicrob Chemother, vol.43, issue.4, pp.523-530, 1999.

S. Dhaese, A. Thooft, A. Farkas, J. Lipman, A. G. Verstraete et al., Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study, J Crit Care, vol.52, pp.75-84, 2019.

G. Aubert, A. Carricajo, M. Coudrot, S. Guyomarc'h, C. Auboyer et al., Prospective determination of serum ceftazidime concentrations in intensive care units, Ther Drug Monit, 2010.

J. J. De-waele, I. Danneels, P. Depuydt, J. Decruyenaere, M. Bourgeois et al., Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion, Int J Antimicrob Agents, vol.41, issue.5, pp.434-442, 2013.

C. Carrié, L. Petit, N. Houdain, N. Sauvage, V. Cottenceau et al., Association between augmented renal clearance, antibiotic exposure and clinical outcome in critically ill septic patients receiving high doses of ?-lactams administered by continuous infusion: a prospective observational study, Int J Antimicrob Agents, vol.51, issue.3, pp.443-452, 2018.

A. A. Udy, J. J. De-waele, and J. Lipman, Augmented renal clearance and therapeutic monitoring of ?-lactams, Int J Antimicrob Agents, vol.45, issue.4, pp.331-334, 2015.

. Research-c-for, .. De, and . Fda-drug, fdadrug-safety-communication-cefepime-and-risk-seizure-patients-not-receiving-dosageadjustments 34. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient, Crit Care Med, vol.37, issue.3, pp.840-51, 2009.

J. Zander, G. Döbbeler, D. Nagel, C. Scharf, M. Huseyn-zada et al., Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients, Int J Antimicrob Agents, vol.48, issue.4, pp.435-444, 2016.

J. A. Roberts, F. Pea, and J. Lipman, The clinical relevance of plasma protein binding changes

, Clin Pharmacokinet, vol.52, issue.1, pp.1-8, 2013.

G. Wong, S. Briscoe, A. S. Mcwhinney, B. Ungerer, J. Lipman et al., Protein binding of ?-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?, Antimicrob Agents Chemother, vol.57, issue.12, pp.6165-70, 2013.

L. Z. Benet and B. Hoener, Changes in plasma protein binding have little clinical relevance, Clin Pharmacol Ther, vol.71, issue.3, pp.115-136, 2002.

L. E. Payne, D. J. Gagnon, R. R. Riker, D. B. Seder, E. K. Glisic et al., Cefepime-induced neurotoxicity: a systematic review. Crit Care Lond Engl, vol.21, p.276, 2017.

T. Huwyler, L. Lenggenhager, M. Abbas, K. Ing-lorenzini, S. Hughes et al.,

, Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.23, issue.7, pp.454-463, 2017.

F. Lamoth, T. Buclin, A. Pascual, S. Vora, S. Bolay et al., High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function, Antimicrob Agents Chemother, vol.54, issue.10, pp.4360-4367, 2010.

J. J. De-waele, J. Lipman, M. Akova, M. Bassetti, G. Dimopoulos et al., Risk factors for target non-attainment during empirical treatment with ?-lactam antibiotics in critically ill patients, Intensive Care Med, vol.40, issue.9, pp.1340-51, 2014.

J. A. Roberts, M. Ulldemolins, M. S. Roberts, B. Mcwhinney, J. Ungerer et al., Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept, Int J Antimicrob Agents, vol.36, issue.4, pp.332-341, 2010.

F. B. Sime, M. S. Roberts, S. L. Peake, J. Lipman, and J. A. Roberts, Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care, vol.2, p.35, 2012.

J. J. De-waele, S. Carrette, M. Carlier, V. Stove, J. Boelens et al., Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial, Intensive Care Med, vol.40, issue.3, pp.380-387, 2014.

C. Economou, G. Wong, B. Mcwhinney, J. Ungerer, J. Lipman et al., Impact of ?-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy, Int J Antimicrob Agents, vol.49, issue.5, pp.589-94, 2017.

B. M. Patel, J. Paratz, N. C. See, M. J. Muller, M. Rudd et al., Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study, Ther Drug Monit, vol.34, issue.2, pp.160-164, 2012.

N. Blondiaux, F. Wallet, R. Favory, T. Onimus, S. Nseir et al., Daily serum piperacillin monitoring is advisable in critically ill patients, Int J Antimicrob Agents, vol.35, issue.5, pp.500-503, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00578296

S. Deshayes, A. Coquerel, and R. Verdon, Neurological Adverse Effects Attributable to ?-Lactam Antibiotics: A Literature Review, Drug Saf, vol.40, issue.12, pp.1171-98, 2017.

D. Silva, D. A. Pan, A. Lim, and S. , Cefepime-induced encephalopathy with triphasic waves in three Asian patients, Ann Acad Med, vol.36, issue.6, pp.450-451, 2007.

U. K. Misra, J. Kalita, S. Chandra, and P. P. Nair, Association of antibiotics with status epilepticus

, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, vol.34, issue.3, pp.327-358, 2013.

J. M. Dulhunty, J. A. Roberts, J. S. Davis, S. Webb, R. Bellomo et al.,

, Multicenter Randomized Trial of Continuous versus Intermittent ?-Lactam Infusion in Severe Sepsis, Am J Respir Crit Care Med, vol.192, issue.11, pp.1298-305, 201501.

S. Y. Lee, J. L. Kuti, and D. P. Nicolau, Cefepime pharmacodynamics in patients with extended spectrum ?-lactamase (ESBL) and non-ESBL infections, J Infect, vol.54, issue.5, pp.463-471, 2007.

J. A. Roberts, J. J. De-waele, G. Dimopoulos, D. Koulenti, C. Martin et al., DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic, BMC Infect Dis, vol.12, p.152, 2012.

M. H. Abdul-aziz, H. Sulaiman, M. Mat-nor, V. Rai, K. K. Wong et al., BetaLactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med, vol.42, issue.10, pp.1535-1580, 2016.

, Lactams continuous infusion in intensive care unit patients : target attainment, variability factors and therapeutic drug monitoring

, Covariates associated with target attainment in patient presented dosage adjustment or not Supplementary Figure 1: Percentage of patient normodosed, overdosed or underdosed at D1, D4 and D7 for documented infections : a) cefepime, n= 82, b) ceftazidime, n=64, c) cefotaxime, n=113 and d) meropenem, vol.5, p.50

, Supplementary Figure 2 : Evolution of patients underdosed, normodosed and overdosed at D1, D4 and D7, owing to dosage adjustment ?? or not

, Bibliographie 1. Surveillance de la consommation des antibiotiques / 2018 / Maladies infectieuses / Rapports et synthèses / Publications et outils / Accueil [Internet, vol.8, pp.5-12, 2013.

N. Petrosillo, C. M. Drapeau, M. Agrafiotis, and M. E. Falagas, Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care, Minerva Anestesiol, vol.76, issue.7, pp.509-533, 2010.

J. A. Roberts and J. Lipman, Pharmacokinetic issues for antibiotics in the critically ill patient, Crit Care Med, vol.37, issue.3, pp.840-51, 2009.

J. A. Roberts, P. Kruger, D. L. Paterson, and J. Lipman, Antibiotic resistance--what's dosing got to do with it? Crit Care Med, vol.36, pp.2433-2473, 2008.

R. Guilhaumou, S. Benaboud, Y. Bennis, C. Dahyot-fizelier, E. Dailly et al., Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR), Crit Care Lond Engl, vol.23, issue.1, p.104, 2019.

J. A. Roberts, A. Davis, J. S. Dulhunty, J. M. Cotta, M. O. Myburgh et al., Continuous versus Intermittent ?-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials, Am J Respir Crit Care Med, 2016.

A. Lal, P. Jaoude, and A. A. El-solh, Prolonged versus Intermittent Infusion of ?-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis. Infect Chemother, vol.48, pp.81-90, 2016.

Y. R. Lee, P. D. Miller, S. K. Alzghari, D. D. Blanco, J. D. Hager et al., Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis, Eur J Drug Metab Pharmacokinet, 2018.

M. H. Abdul-aziz, J. Lipman, M. Akova, M. Bassetti, J. J. De-waele et al., Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort, J Antimicrob Chemother, vol.71, issue.1, pp.196-207, 2016.

R. De-jongh, R. Hens, V. Basma, J. W. Mouton, P. M. Tulkens et al., Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection, J Antimicrob Chemother, vol.61, issue.2, pp.382-390, 2008.

W. A. Krueger, J. Bulitta, M. Kinzig-schippers, C. Landersdorfer, U. Holzgrabe et al., Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers, Antimicrob Agents Chemother, vol.49, issue.5, pp.1881-1890, 2005.

F. S. Taccone, P. Laterre, T. Dugernier, H. Spapen, I. Delattre et al., Insufficient ?-lactam concentrations in the early phase of severe sepsis and septic shock, Crit Care Lond Engl, vol.14, issue.4, p.126, 2010.

M. F. Grill and R. K. Maganti, Neurotoxic effects associated with antibiotic use: management considerations, Br J Clin Pharmacol, vol.72, issue.3, pp.381-93, 2011.

K. M. Chow, A. C. Hui, and C. C. Szeto, Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside, Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol, vol.24, issue.10, pp.649-53, 2005.

. Céfépime, Axepim® et ses génériques) : rappel des risques d'effets indésirables neurologiques graves lors du non-respect des posologies recommandées notamment en cas d'insuffisance rénale -Lettre aux professionnels de santé -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2019.

C. Lacroix, F. Kheloufi, F. Montastruc, Y. Bennis, V. Pizzoglio et al., Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database, J Neurol Sci, 2019.

M. Quirins and N. Weiss, Encéphalopathies médicamenteuses, une approche pratique pour le clinicien. Prat Neurol -FMC, vol.5, pp.39-48, 2014.

S. Deshayes, A. Coquerel, and R. Verdon, Neurological Adverse Effects Attributable to ?-Lactam Antibiotics: A Literature Review, Drug Saf, vol.40, issue.12, pp.1171-98, 2017.

D. Silva, D. A. Pan, A. Lim, and S. , Cefepime-induced encephalopathy with triphasic waves in three Asian patients, Ann Acad Med, vol.36, issue.6, pp.450-451, 2007.

U. K. Misra, J. Kalita, S. Chandra, and P. P. Nair, Association of antibiotics with status epilepticus

, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, vol.34, issue.3, pp.327-358, 2013.

J. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto et al., International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, JAMA, vol.302, issue.21, pp.2323-2332, 2009.

R. P. Dellinger, M. M. Levy, A. Rhodes, D. Annane, H. Gerlach et al., Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, Intensive Care Med, vol.39, issue.2, pp.165-228, 2012.

M. Singer, C. S. Deutschman, C. W. Seymour, M. Shankar-hari, D. Annane et al.,

, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA, vol.315, issue.8, pp.801-811, 2016.

M. Shankar-hari and M. Singer, Defining Septic Shock-Reply, JAMA, vol.316, issue.4, pp.456-456, 2016.

J. Quenot, C. Binquet, F. Kara, O. Martinet, F. Ganster et al., The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit Care, vol.17, p.65, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00873494

R. C. Bone, R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, The ACCP/SCCM Consensus Conference Committee, vol.101, pp.1644-55, 1992.

D. Annane, E. Bellissant, and J. Cavaillon, Septic shock, Lancet Lond Engl, vol.365, issue.9453, pp.63-78, 2005.
URL : https://hal.archives-ouvertes.fr/hal-02159416

J. S. Boomer, K. To, K. C. Chang, O. Takasu, D. F. Osborne et al., Immunosuppression in patients who die of sepsis and multiple organ failure, 31. van der Poll T, Opal SM, vol.306, pp.2594-605, 2008.

W. A. Craig, Choosing an antibiotic on the basis of pharmacodynamics, Ear Nose Throat J

A. U. Gerber, W. A. Craig, H. P. Brugger, C. Feller, A. P. Vastola et al., Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice, J Infect Dis, vol.147, issue.5, pp.910-917, 1983.

W. A. Craig, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.26, issue.1, pp.11-13, 1998.

J. A. Roberts, J. J. De-waele, G. Dimopoulos, D. Koulenti, C. Martin et al., DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic, BMC Infect Dis, vol.12, p.152, 2012.

J. W. Mouton, N. Punt, and A. A. Vinks, Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo, Antimicrob Agents Chemother, vol.51, issue.9, pp.3449-51, 2007.

J. F. Mohr, A. Wanger, and J. H. Rex, Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients, Diagn Microbiol Infect Dis, vol.48, issue.2, pp.125-155, 2004.

P. S. Mckinnon, J. A. Paladino, and J. J. Schentag, Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections, Int J Antimicrob Agents, 2008.

P. Seguin, M. C. Verdier, C. Chanavaz, C. Engrand, B. Laviolle et al., Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis, J Antimicrob Chemother, vol.63, issue.3, pp.564-571, 2009.

J. M. Dulhunty, J. A. Roberts, J. S. Davis, S. Webb, R. Bellomo et al., Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.56, issue.2, pp.498-509, 2013.

A. A. Udy, J. J. De-waele, and J. Lipman, Augmented renal clearance and therapeutic monitoring of ?-lactams, Int J Antimicrob Agents, vol.45, issue.4, pp.331-334, 2015.

F. B. Sime, A. A. Udy, and J. A. Roberts, Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization, Curr Opin Pharmacol, vol.24, pp.1-6, 2015.

M. Ulldemolins, J. A. Roberts, J. Rello, D. L. Paterson, and J. Lipman, The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients, Clin Pharmacokinet, vol.50, issue.2, pp.99-110, 2011.

G. Wong, S. Briscoe, A. S. Mcwhinney, B. Ungerer, J. Lipman et al., Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of ?-lactams, Antimicrob Agents Chemother, vol.57, issue.12, p.206, 2011.

G. Aubert, A. Carricajo, M. Coudrot, S. Guyomarc'h, C. Auboyer et al., Prospective determination of serum ceftazidime concentrations in intensive care units, Ther Drug Monit

F. Pea, F. Pavan, and M. Furlanut, Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients, Clin Pharmacokinet, vol.47, issue.7, pp.449-62, 2008.

J. J. De-waele, D. Neve, and N. , Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring, Minerva Anestesiol, 2014.

I. K. Delattre, F. T. Musuamba, R. K. Verbeeck, T. Dugernier, H. Spapen et al., Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin, Clin Biochem, vol.43, issue.6, pp.589-98, 2010.

I. K. Delattre, F. T. Musuamba, P. Jacqmin, F. S. Taccone, P. Laterre et al., Population pharmacokinetics of four ?-lactams in critically ill septic patients comedicated with amikacin, Clin Biochem, vol.45, pp.780-786, 2012.

J. J. De-waele, S. Carrette, M. Carlier, V. Stove, J. Boelens et al., Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial, Intensive Care Med, vol.40, issue.3, pp.380-387, 2014.

A. Fournier, P. Eggimann, J. Pagani, J. Revelly, L. A. Decosterd et al., Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients, Burns J Int Soc Burn Inj, vol.41, issue.5, pp.956-68, 2015.

C. Economou, G. Wong, B. Mcwhinney, J. Ungerer, J. Lipman et al., Impact of ?-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy, Int J Antimicrob Agents, vol.49, issue.5, pp.589-94, 2017.

N. Blondiaux, F. Wallet, R. Favory, T. Onimus, S. Nseir et al., Daily serum piperacillin monitoring is advisable in critically ill patients, Int J Antimicrob Agents, vol.35, issue.5, pp.500-503, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00578296

J. A. Roberts, M. Ulldemolins, M. S. Roberts, B. Mcwhinney, J. Ungerer et al., Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept, Int J Antimicrob Agents, vol.36, issue.4, pp.332-341, 2010.

M. Carlier, V. Stove, S. C. Wallis, J. J. De-waele, A. G. Verstraete et al., Assays for therapeutic drug monitoring of ?-lactam antibiotics: A structured review, Int J Antimicrob Agents, vol.46, issue.4, pp.367-75, 2015.

R. Rigo-bonnin, R. Juvany-roig, E. Leiva-badosa, J. Sabater-riera, X. L. Pérez-fernández et al., Measurement of meropenem concentration in different human biological fluids by ultra-performance liquid chromatography-tandem mass spectrometry, Anal Bioanal Chem, vol.406, issue.20, pp.4997-5007, 2014.

S. I. Blot, F. Pea, and J. Lipman, The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents, Adv Drug Deliv Rev, vol.77, pp.3-11, 2014.

P. Longuet, A. L. Lecapitaine, B. Cassard, R. Batista, R. Gauzit et al., Preparing and administering injectable antibiotics: How to avoid playing God, Med Mal Infect, 2016.

M. Beumier, G. S. Casu, M. Hites, F. Wolff, F. Cotton et al., Elevated ?-lactam concentrations associated with neurological deterioration in ICU septic patients, Minerva Anestesiol, vol.81, issue.5, pp.497-506, 2015.

M. Verdier, O. Tribut, P. Tattevin, L. Tulzo, Y. Michelet et al., Simultaneous Determination of 12 ?-Lactam Antibiotics in Human Plasma by High-Performance Liquid Chromatography with UV Detection: Application to Therapeutic Drug Monitoring?, Antimicrob Agents Chemother, vol.55, issue.10, pp.4873-4882, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00875271

S. Dhaese, A. Thooft, A. Farkas, J. Lipman, A. G. Verstraete et al., Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study, J Crit Care, vol.52, pp.75-84, 2019.

Y. Hayashi, J. Lipman, A. A. Udy, M. Ng, B. Mcwhinney et al., ?-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia, Int J Antimicrob Agents, vol.41, issue.2, pp.162-168, 2013.

C. Carrié, R. Legeron, L. Petit, J. Ollivier, V. Cottenceau et al., Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion, J Crit Care, vol.48, pp.66-71, 2018.

A. Huttner, V. Dach, E. Renzoni, A. Huttner, B. D. Affaticati et al.,

, Augmented renal clearance, low ?-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study, Int J Antimicrob Agents, vol.45, issue.4, pp.385-92, 2015.

J. Conil, B. Georges, O. Mimoz, E. Dieye, S. Ruiz et al., Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients, Intensive Care Med, vol.32, issue.12, pp.2063-2069, 2006.

L. E. Payne, D. J. Gagnon, R. R. Riker, D. B. Seder, E. K. Glisic et al., FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment, vol.21, 2017.

, Clin Pharmacokinet, vol.52, issue.1, pp.1-8, 2013.

L. Z. Benet and B. Hoener, Changes in plasma protein binding have little clinical relevance

, Clin Pharmacol Ther, vol.71, issue.3, pp.115-136, 2002.

T. Huwyler, L. Lenggenhager, M. Abbas, K. Ing-lorenzini, S. Hughes et al.,

, Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study, Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis, vol.23, issue.7, pp.454-463, 2017.

T. M. Chapuis, E. Giannoni, P. A. Majcherczyk, R. Chioléro, M. Schaller et al., Prospective monitoring of cefepime in intensive care unit adult patients, Crit Care Lond Engl, vol.14, issue.2, p.51, 2010.

F. Lamoth, T. Buclin, A. Pascual, S. Vora, S. Bolay et al., High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function, Antimicrob Agents Chemother, vol.54, issue.10, pp.4360-4367, 2010.

M. Leone, A. Bourgoin, S. Cambon, M. Dubuc, J. Albanèse et al., Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome, Crit Care Med, vol.31, issue.2, pp.462-469, 2003.

B. M. Patel, J. Paratz, N. C. See, M. J. Muller, M. Rudd et al., Therapeutic drug monitoring of beta-lactam antibiotics in burns patients--a one-year prospective study, Ther Drug Monit, vol.34, issue.2, pp.160-164, 2012.

M. H. Abdul-aziz, H. Sulaiman, M. Mat-nor, V. Rai, K. K. Wong et al., BetaLactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med, vol.42, issue.10, pp.1535-1580, 2016.